Skip to main content

Table 1 Characteristics of patients with refractory germ cell tumors enrolled in the sutent phase 2 study and outcomes at presentation

From: Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial

Pt # Race Age ++ PS Primary mass Pathology- Components Prior Therapies AFP ng/ml (0–5.0) B-HCG mIU/ml (0–1) LDHIU/L (313–618)
1 AA 17 0 Testis Seminoma;Embryonal, Choriocarcinoma, Immature teratoma, Mature teratoma. R orchiectomy, BEP × 4, RPLND,TIP, Gem + Etoposide, Avastin + Gem, Avatin, Taxol, Gem, 18495.6 <1.0 2386
2 Asian 20 0 Mediastinum Yolk sac tumor, Endodermal Sinus Tumor. BEP × 3, TIP × 2, Surgery- multiple, ACE × 2 2087.9 <1.0 419
3 White 36 1 Testis Embryonal Carcinoma (80%) and yolk sac tumor (20%) R orchiectomy, BEP × 3, RPLND,TIP × 4, XRT- T10 -L2 , Cisplatin + Epirubicin × 4, XRT to R chest wall, WBRT, Oxaliplatin + Gem, × 4, Oxaliplatin × 8, Gem × 3, etoposide × 3 108.9 <1.1 524
4 White 19 1 Retro-peritoneal mass Teratoma and Choriocarcinoma BEP × 4, TIP × 1, VIP × 5, HD-SCT with carboplatin + etoposide, RPLND, 1.1 227865.8 794
5 White 29 and 52* 1 Testis Embryonal Carcinoma (80%) and yolk sac tumor (20%) R orchiectomy, 20 yrs later BEP × 3, EP × 1, RPLND, TIP × 2, ACE × 1 235.5 19.8 635
  1. Abbreviations: ++Age Age at original diagnosis, PS Performance status, *Age at relapse, AA African American, R Right, BEP Bleiomycin, Etoposide, Cisplatin, RPLND Retroperitoneal Lymph node dissection, TIP Taxol, Ifosfamide, Cisplatin, VIP VP-16, Ifosfamide, Cisplatin, ACE Actinomycin, Cyclophosphamide, Etoposide. Gem Gemcitabine.